- Home
- PCVX vs MSGS Comparison
PCVX vs MSGS Comparison
Compare PCVX & MSGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | MSGS |
|---|---|---|
| Founded | 2013 | 1879 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 7.8B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PCVX | MSGS |
|---|---|---|
| Price | $62.08 | $329.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $88.25 | ★ $326.29 |
| AVG Volume (30 Days) | ★ 1.2M | 185.9K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.09 | $183.58 |
| 52 Week High | $65.00 | $345.46 |
Technical Indicators
Market Signals| Indicator | PCVX | MSGS |
|---|---|---|
| Relative Strength Index (RSI) | 63.13 | 59.20 |
| Support Level | $42.30 | $303.92 |
| Resistance Level | $65.00 | $335.08 |
| Average True Range (ATR) | 2.30 | 8.13 |
| MACD | 0.60 | 0.74 |
| Stochastic Oscillator | 85.71 | 81.05 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.